<DOC>
	<DOCNO>NCT01107093</DOCNO>
	<brief_summary>Evaluation effect single dose CDB-2914 , compare placebo , administer onset LH surge outcome lead ovary follicle : - echographic follicle rupture - inhibition follicle rupture - luteal phase progesterone level - anovulatory progesterone level</brief_summary>
	<brief_title>Comparison CDB-2914 Versus Placebo Prevention Follicular Rupture Post-luteinizing Hormone ( LH ) Surge</brief_title>
	<detailed_description />
	<mesh_term>Rupture</mesh_term>
	<criteria>Women good general health age 18 35 year Not risk pregnancy Regular menstrual cycle 2435 day duration Not pregnant Intact uterus ovary Haemoglobin â‰¥ 11 g/dl Normal laboratory test normal TSH Willing abstain use hormonal contraception study completion No current use hormonal contraception least one complete menstrual cycle ( 2 menses ) since termination previous hormonal contraception Had least one complete menstrual cycle ( 2 menses ) follow delivery , miscarriage induce abortion Able give voluntary , write informed consent , agree observe study requirement 5 complete menstrual cycle Current participation trial investigational medicine Known hypersensitivity ingredient test active substance excipients Suspected hyperplasia carcinoma endometrium Current pregnancy confirm positive serum betahCG screen Desire get pregnant plan end study participation Currently breastfeed Abnormal Pap smear Cancer ( past history carcinoma sarcoma ) Known suspect alcoholism drug abuse Abnormal thyroid status Body mass index &gt; 32 Current use hormonal contraception Use hormonal emergency contraception since last menstrual period Severe asthma insufficiently control oral glucocorticoid Hereditary galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>